OBJECTIVE: The aim of the study was to examine the dose effects of Lactobacillus acidophilus (LA) NCFM strain on rotavirus-specific antibody and B-cell responses in gnotobiotic pigs vaccinated with an oral attenuated human rotavirus (AttHRV). METHODS: Pigs were inoculated with AttHRV vaccine in conjunction with high-dose LA (14 doses, total 2.2 × 10(6) colony-forming units [CFU]), intermediate-dose LA (MidLA) (9 doses, total 3.2 × 10(9) CFU), low-dose LA (LoLA) (5 doses, total 2.1 × 10(6) CFU), or without LA feeding. Protection against rotavirus shedding and diarrhea was assessed upon challenge with a virulent HRV. Rotavirus-specific immunoglobulin A (IgA) and IgG antibodies in serum and rotavirus-specific IgA and IgG antibody-secreting cells (ASCs) and memory B cells in ileum, spleen, and blood of the pigs were measured and compared among treatment groups. RESULTS: The MidLA, but not high-dose LA or LoLA, significantly reduced rotavirus diarrhea (MidLA-only group) and significantly improved the protection conferred by AttHRV vaccine (MidLA + AttHRV group). Associated with the increased protection, MidLA significantly enhanced rotavirus-specific antibody, ASCs, and memory B-cell responses to AttHRV vaccine. High-dose LA or LoLA did not enhance virus-specific antibody and ASC responses, and hence did not improve the vaccine efficacy. CONCLUSIONS: These findings highlight the importance of dose selection and indicate that certain specific lactobacilli strains at the appropriate dose have the dual function of reducing rotavirus diarrhea and enhancing the immunogenicity and protective efficacy of rotavirus vaccines.
OBJECTIVE: The aim of the study was to examine the dose effects of Lactobacillus acidophilus (LA) NCFM strain on rotavirus-specific antibody and B-cell responses in gnotobiotic pigs vaccinated with an oral attenuated human rotavirus (AttHRV). METHODS:Pigs were inoculated with AttHRV vaccine in conjunction with high-dose LA (14 doses, total 2.2 × 10(6) colony-forming units [CFU]), intermediate-dose LA (MidLA) (9 doses, total 3.2 × 10(9) CFU), low-dose LA (LoLA) (5 doses, total 2.1 × 10(6) CFU), or without LA feeding. Protection against rotavirus shedding and diarrhea was assessed upon challenge with a virulent HRV. Rotavirus-specific immunoglobulin A (IgA) and IgG antibodies in serum and rotavirus-specific IgA and IgG antibody-secreting cells (ASCs) and memory B cells in ileum, spleen, and blood of the pigs were measured and compared among treatment groups. RESULTS: The MidLA, but not high-dose LA or LoLA, significantly reduced rotavirus diarrhea (MidLA-only group) and significantly improved the protection conferred by AttHRV vaccine (MidLA + AttHRV group). Associated with the increased protection, MidLA significantly enhanced rotavirus-specific antibody, ASCs, and memory B-cell responses to AttHRV vaccine. High-dose LA or LoLA did not enhance virus-specific antibody and ASC responses, and hence did not improve the vaccine efficacy. CONCLUSIONS: These findings highlight the importance of dose selection and indicate that certain specific lactobacilli strains at the appropriate dose have the dual function of reducing rotavirus diarrhea and enhancing the immunogenicity and protective efficacy of rotavirus vaccines.
Authors: Michael de Vrese; Peter Rautenberg; Christiane Laue; Marion Koopmans; Tineke Herremans; Jürgen Schrezenmeir Journal: Eur J Nutr Date: 2004-12-01 Impact factor: 5.614
Authors: L Gackowska; J Michalkiewicz; M Krotkiewski; A Helmin-Basa; I Kubiszewska; D Dzierzanowska Journal: J Physiol Pharmacol Date: 2006-11 Impact factor: 3.011
Authors: Alain P Vicari; Tess Schmalbach; Julie Lekstrom-Himes; Mary Louise Morris; Mohammed J Al-Adhami; Chantal Laframboise; Philip Leese; Arthur M Krieg; Susan M Efler; Heather L Davis Journal: Antivir Ther Date: 2007
Authors: M Rigo-Adrover; S Saldaña-Ruíz; K van Limpt; K Knipping; J Garssen; J Knol; A Franch; M Castell; F J Pérez-Cano Journal: Eur J Nutr Date: 2016-04-25 Impact factor: 5.614
Authors: Qinghui Mu; Husen Zhang; Xiaofeng Liao; Kaisen Lin; Hualan Liu; Michael R Edwards; S Ansar Ahmed; Ruoxi Yuan; Liwu Li; Thomas E Cecere; David B Branson; Jay L Kirby; Poorna Goswami; Caroline M Leeth; Kaitlin A Read; Kenneth J Oestreich; Miranda D Vieson; Christopher M Reilly; Xin M Luo Journal: Microbiome Date: 2017-07-11 Impact factor: 14.650
Authors: Maria Del Mar Rigo-Adrover; Kees van Limpt; Karen Knipping; Johan Garssen; Jan Knol; Adele Costabile; Àngels Franch; Margarida Castell; Francisco José Pérez-Cano Journal: Front Immunol Date: 2018-06-11 Impact factor: 7.561
Authors: Leila Abdelhamid; Xavier Cabana-Puig; Brianna Swartwout; Jiyoung Lee; Song Li; Sha Sun; Yaqi Li; A Catharine Ross; Thomas E Cecere; Tanya LeRoith; Stephen R Werre; Haifeng Wang; Christopher M Reilly; Xin M Luo Journal: Front Immunol Date: 2020-03-20 Impact factor: 7.561